Verona Pharma plc Verona Pharma To Present At Jefferies 2019 London Healthcare Conference

 
TIDMVRP 
 
   LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on respiratory diseases, announces that Jan-Anders 
Karlsson, CEO of Verona Pharma, will present a corporate overview and 
host one-on-one meetings with investors at the Jefferies 2019 London 
Healthcare Conference taking place November 20-21, 2019. 
 
   Presentation details are as follows: 
 
 
 
 
Date:              Wednesday, November 20, 2019 
 Time:              5:20 PM GMT (12:20 PM ET) 
 Location:          London, UK 
 Webcast Details:   http://wsw.com/webcast/jeff123/vrna/ http://wsw.com/webcast/jeff123/vrna/ 
                   -------------------------------------------------------------------------- 
 
   For more information, please visit 
https://www.globenewswire.com/Tracker?data=8f2SOb_6KGgMn_ePulOtdd0NIu8Tx3nZYailhZBU9Ct-sXlMC7kakSBBA-N9JD6p-_fGiNYL7GU8LuXt5XUi26Z76yAckE_rCrZmURDYDkdDE33ZRTk8r4HyO-Zt18Ah 
investors.veronapharma.com. 
 
   About the Jefferies 2019 London Healthcare Conference 
 
   This year marks the 10th anniversary of The Jefferies 2019 London 
Healthcare Conference, now one of the largest healthcare-dedicated 
conference in Europe. In 2018, 500 companies and 2,000 attendees 
participated in the conference, which featured 5,000 
business-to-business and investor meetings. This event will again 
feature leading public and private companies from the pharmaceuticals, 
biotechnology, generics, consumer health, animal health, medical 
technology and healthcare services sectors from the United States, 
Europe, Africa, Middle East, Latin America, Russia, India, Israel, China 
and Japan. 
 
   About Verona Pharma 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, ensifentrine, has the potential to be the 
first novel class of bronchodilator in over 40 years, and the first 
therapy for the treatment of respiratory diseases that combines 
bronchodilator and anti-inflammatory activities in one compound. Verona 
Pharma is currently in Phase 2 development of three formulations of 
ensifentrine for the treatment of COPD: nebulized, dry powder inhaler, 
and pressurized metered-dose inhaler. Ensifentrine also has potential 
applications in cystic fibrosis, asthma and other respiratory diseases. 
For more information, please visit 
https://www.globenewswire.com/Tracker?data=81aS7vjXeUqfAdVPOTD7YrtH7mvzvcm5AGtrKf_F-HAl83UMNHTe_TDVq17v6euy-BE0MwxtFh_5756NKdeExD8OulWUiMjKKbA8P_P_Jb4= 
www.veronapharma.com. 
 
   Forward-Looking Statements 
 
   This press release contains forward-looking statements. All statements 
contained in this press release that do not relate to matters of 
historical fact should be considered forward-looking statements, 
including, but not limited to, the development of ensifentrine, the 
progress and timing of clinical trials and data, estimates of medical 
costs for COPD, ensifentrine as a first-in-class phosphodiesterase 3 and 
4 inhibitor, and plans to develop ensifentrine for the treatment of 
cystic fibrosis and asthma. 
 
   These forward-looking statements are based on management's current 
expectations. These statements are neither promises nor guarantees, but 
involve known and unknown risks, uncertainties and other important 
factors that may cause our actual results, performance or achievements 
to be materially different from our expectations expressed or implied by 
the forward-looking statements, including, but not limited to, the 
following: our limited operating history; our need for additional 
funding to complete development and commercialization of ensifentrine, 
which may not be available and which may force us to delay, reduce or 
eliminate our development or commercialization efforts; the reliance of 
our business on the success of ensifentrine, our only product candidate 
under development; economic, political, regulatory and other risks 
involved with international operations; the lengthy and expensive 
process of clinical drug development, which has an uncertain outcome; 
serious adverse, undesirable or unacceptable side effects associated 
with ensifentrine, which could adversely affect our ability to develop 
or commercialize ensifentrine; potential delays in enrolling patients, 
which could adversely affect our research and development efforts and 
the completion of our Phase 2b trial; we may not be successful in 
developing ensifentrine for multiple indications; our ability to obtain 
approval for and commercialize ensifentrine in multiple major 
pharmaceutical markets; misconduct or other improper activities by our 
employees, consultants, principal investigators, and third-party service 
providers; material differences between our "top-line" data and final 
data; our reliance on third parties, including clinical investigators, 
manufacturers and suppliers, and the risks related to these parties' 
ability to successfully develop and commercialize ensifentrine; and 
lawsuits related to patents covering ensifentrine and the potential for 
our patents to be found invalid or unenforceable. These and other 
important factors under the caption "Risk Factors" in our Annual Report 
on Form 20-F filed with the Securities and Exchange Commission ("SEC") 
on March 19, 2019, and our other reports filed with the SEC, could cause 
actual results to differ materially from those indicated by the 
forward-looking statements made in this press release. Any such 
forward-looking statements represent management's estimates as of the 
date of this press release. While we may elect to update such 
forward-looking statements at some point in the future, we disclaim any 
obligation to do so, even if subsequent events cause our views to 
change. These forward-looking statements should not be relied upon as 
representing our views as of any date subsequent to the date of this 
press release. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                    Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer         info@veronapharma.com 
Victoria Stewart, Director of Communications 
 
N+1 Singer                                           Tel: +44 (0)20 3283 4200 
 (Nominated Adviser and UK Broker) 
Aubrey Powell / George Tzimas (Corporate Finance) 
Mia Gardner (Corporate Broking) 
 
Optimum Strategic Communications                     Tel: +44 (0)20 950 9144 
 (European Media and Investor Enquiries)              verona@optimumcomms.com 
Mary Clark / Eva Haas / Hollie Vile 
 
Argot Partners                                       Tel: +1 212-600-1902 
 (US Investor Enquiries)                              verona@argotpartners.com 
Stephanie Marks / Kimberly Minarovich / Michael 
Barron
(END) Dow Jones Newswires
November 13, 2019 02:00 ET (07:00 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024